Cargando…
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
AIMS/INTRODUCTION: Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiv...
Autores principales: | Utsunomiya, Kazunori, Kakiuchi, Seigo, Senda, Masayuki, Fujii, Shoko, Kurihara, Yuji, Gunji, Ryoji, Koshida, Ryusuke, Kameda, Hiroyuki, Tamura, Masahiro, Kaku, Kohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378444/ https://www.ncbi.nlm.nih.gov/pubmed/32034997 http://dx.doi.org/10.1111/jdi.13233 |
Ejemplares similares
-
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2020) -
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2019) -
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2019) -
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study)
por: Utsunomiya, Kazunori, et al.
Publicado: (2017) -
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)
por: Kaku, Kohei, et al.
Publicado: (2019)